Free Trial
NASDAQ:CBIO

Crescent Biopharma (CBIO) Stock Price, News & Analysis

Crescent Biopharma logo
$16.90 -1.10 (-6.11%)
As of 06/26/2025 04:00 PM Eastern

About Crescent Biopharma Stock (NASDAQ:CBIO)

Key Stats

Today's Range
$15.51
$18.89
50-Day Range
N/A
52-Week Range
$11.06
$63.00
Volume
109,227 shs
Average Volume
64,475 shs
Market Capitalization
$10.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Strong Buy

Company Overview

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

CBIO MarketRank™: 

Crescent Biopharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 390th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crescent Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.67, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Crescent Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Crescent Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crescent Biopharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crescent Biopharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crescent Biopharma has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CBIO.
  • Dividend Yield

    Crescent Biopharma does not currently pay a dividend.

  • Dividend Growth

    Crescent Biopharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CBIO.
  • News Sentiment

    Crescent Biopharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for CBIO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crescent Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Crescent Biopharma is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crescent Biopharma's insider trading history.
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

Stifel Nicolaus Begins Coverage on Crescent Biopharma (NASDAQ:CBIO)
Crescent Biopharma Inc. CBIO Company Vitals - U.S. News
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Catalyst Biosciences, Inc. (CBIO)
Catalyst Biosciences Inc trading halted, volatility trading pause
See More Headlines

CBIO Stock Analysis - Frequently Asked Questions

Crescent Biopharma's stock was trading at $15.7950 on January 1st, 2025. Since then, CBIO stock has increased by 7.0% and is now trading at $16.90.
View the best growth stocks for 2025 here
.

Crescent Biopharma, Inc. (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) EPS for the quarter, meeting the consensus estimate of ($7.00).

Crescent Biopharma shares reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/17/2023
Today
6/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
Previous Symbol
NASDAQ:CBIO
Employees
26
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$28.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+47.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Pretax Margin
-397,340.00%

Debt

Sales & Book Value

Annual Sales
$10 thousand
Price / Cash Flow
N/A
Book Value
$8.24 per share
Price / Book
2.05

Miscellaneous

Free Float
619,000
Market Cap
$10.99 million
Optionable
No Data
Beta
1.62

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CBIO) was last updated on 6/27/2025 by MarketBeat.com Staff
From Our Partners